Urinary lipocalin-type prostaglandin D synthase: A potential marker for early gentamicin-induced renal damage?

Therapeutic Drug Monitoring

Volumn 31, Issue 1, 2009, Pages 126-130

  Nakayama, Hirokazu ^a,c   Echizen, Hirotoshi ^b   Gomi, Tomoko ^c   Shibuya, Yuko ^c   Nakamura, Yoshitsugu ^c   Nakano, Kiyoharu ^c   Arashi, Hiroyuki ^c   Itai, Tsutomu ^c   Ohnishi, Satoshi ^c   Tanaka, Masayo ^a   Orii, Takao ^a  

^a Sapporo Medical Center   (Japan)

^b MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

^c Kanto Teishin Hospital   (Japan)

Author keywords

Gentamicin; Renal toxicity; Therapeutic drug monitoring; Urinary lipocalin type prostaglandin D synthase

Indexed keywords

BETA 2 MICROGLOBULIN; BETA LACTAM ANTIBIOTIC; BIOLOGICAL MARKER; CARBAPENEM; CREATININE; GENTAMICIN; LIPOCALIN TYPE PROSTAGLANDIN D SYNTHASE; N ACETYL BETA GLUCOSAMINIDASE; PROSTAGLANDIN D SYNTHASE; UNCLASSIFIED DRUG; VANCOMYCIN;

ADULT; AGED; ARTICLE; BACTERIAL ENDOCARDITIS; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; HUMAN; KIDNEY INJURY; MALE; PRIORITY JOURNAL; URINARY EXCRETION;

ACETYLGLUCOSAMINIDASE; ALGORITHMS; ANTI-BACTERIAL AGENTS; BETA 2-MICROGLOBULIN; BIOLOGICAL MARKERS; CREATININE; ENDOCARDITIS, BACTERIAL; FEMALE; GENTAMICINS; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; INTRAMOLECULAR OXIDOREDUCTASES; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; LIPOCALINS; MALE; MIDDLE AGED; PILOT PROJECTS;

EID: 60549117186     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31819566f1     Document Type: Article

References (27)

1. 2 involved in regulation of physiolog-ical sleep. Proc Natl Acad Sci U S A. 2006;103:17949-17954.
2. 2 reduces intraocular pressure. Br J Ophthalmol. 1988;72:461-464.
3. 2 on platelet aggregation in different species. Prostaglandins. 1978;16:373-388.
4. 2 relaxes bovine coronary arteries by endothelium-dependent nitric oxide-mediated cGMP formation. Circ Res. 1992;71:1305-1313.
5. Marom Z, Shelhamer JH, Kaliner M. Effects of arachidonic acid, monohydroxyeicosatetraenoic acid and prostaglandins on the release of mucous glycoproteins from human airway in vitro. J Clin Invest. 1981;67: 1695-1702.
6. Priem F, Althaus H, Birnbaum M, et al. β-trace protein in serum: a new marker of glomerular nitration rate in the creatinine-blind range. Clin Chem. 1999;45:567-568.
7. Woitas RP, Stoffel-Wagner B, Poege U, et al. Low-molecular weight proteins as markers for glomerular filtration rate. Clin Chem. 2001;47: 2179-2180.
8. 2-microglobulin, and creatinine compared for detecting impaired glomerular filtration rates in children. Clin Chem. 2002;48:729-736.
9. Pöge U, Gerhardt TM, Stoffel-Wagner B, et al. β-trace protein is an alternative marker for glomerular filtration rate in renal transplantation patients. Clin Chem. 2005;51:1531-1533.
10. Ogawa M, Hirawa N, Tsuchida T, et al. Urinary excretions of lipocalin-type prostaglandin DT synthase predict the development of proteinuria and renal injury in OLETF rats. Nephrol Dial Transplant. 2006;21:924-934.
11. Hirawa N, Uehara Y, Ikeda T, et al. Urinary prostaglandin D synthase (β-trace) excretion increases in the early stage of diabetes mellitus. Nephron. 2001;87:321-327.
12. Tsuchida T, Eguchi N, Eguchi Y, et al. Lipocalin-type prostaglandin D synthase in urine in adriamycin-induced nephropathy of mice. Nephron Physiol. 2004;96:42-51.
13. Moreillon P, Que YA. Infective endocarditis. Lancet. 2004;363:139-149.
14. Appel GB. Aminoglycoside nephrotoxicity. Am J Med. 1990;88(Suppl 3C):16S-20S.
15. Kirkpatrick CMJ, Duffull SB, Begg EJ, et al. The use of change in gentamicin clearance as an early predictor of gentamicin-induced nephrotoxicity. Ther Drug Monit. 2003;25:623-630.
16. Nix DE, Thomas JK, Symonds WT, et al. Assessment of the enzymuria resulting from gentamicin alone and combinations of gentamicin with various beta-lactam antibiotics. Ann Pharmacother. 1997;31:696-703.
17. Schentag JJ, Meagher AK, Jellife RW. Aminoglycosides. In: Burton ME, Shaw EM, Schentag JJ, et al, eds. Applied Pharmacokinetics and Pharmacodynamics. 4th ed. Philadelphia, PA: Lippincott Williams Wilkins; 2006:286-327.
18. Durack DT, Eukes AS, Bright DK. New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Am J Med. 1994;96:200-209.
19. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the committee on rheumatic fever, endocarditis, and Kawasaki disease, council on cardiovascular disease in the young, and the councils on clinical cardiology, stroke, and cardiovascular surgery and anesthesia, American Heart Association-Executive summary. Circulation. 2005;111:3167-3184.
20. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
21. Oda H, Shiina Y, Seiki K, et al. Development and evaluation of a practical ELISA for human urinary lipocalin-type prostaglandin D synthase. Clin Chem. 2002;48:1445-1453.
22. Beringer P, Winter ME. Aminoglycoside antibiotics. In: Winter ME, ed. Basic Clinical Pharmacokinetics; 4th ed. Philadelphia, PA: Lippincott Williams Wilkins; 2004:130-171.
23. Nakayama H, Echizen H, Tanaka M, et al. Reduced vancomycin clearance despite unchanged creatinine clearance in patients treated with vancomycin for longer than 4 weeks. Ther Drug Monit. 2008;30: 103-107.
24. Sawchuck RJ, Zaske DE. Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients. J Pharmacokinet Biopharm. 1976;4:183-195.
25. Whitsed H, Penny R. β trace protein: purification and urinary excretion studies in selected diseases. Clin Chim Acta. 1974;50:111-118.
26. Hirawa N, Uehara Y, Yamakado M, et al. Lipocalin-type prostaglandin D synthase in essential hypertension. Hypertension. 2002;39:449-454.
27. 2 synthase expression in vascular endothelial cells. Circ Res. 2000;86:967-973.